MajesTEC-4

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4

What's the purpose of the trial?

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Trial status

Accepting patients

Phase

Phase 3

Enrollment

1594

Last Updated

Participating Centers

There are 40 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Lenalidomide
Teclistamab

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Arm A: Teclistamab-Lenalidomide (Tec-Len)

Accepting patients

Arm C: Teclistamab-Alone (Tec)

Accepting patients

Arm B: Lenalidomide Alone (Len)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.